Skip to main content

Table 3 Frequency of adverse events in the two groups

From: Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial

Adverse events

Trearment group

memantine+sertraline

placebo+sertraline

p-value

N

%

N

%

Muscle pain

2

5.7

2

6.7

0.87

Headache

2

5.7

2

6.7

0.87

Diarhea

1

2.9

0

0

0.35

Constipation

0

0

0

0

1

Decreased libido

5

14.3

3

10

0.60

Decreased appetite

5

14.3

3

10

0.60

Lightheadness

1

2.9

0

0

0.35

Palpitation

0

0

1

3.3

0.28

Insomnia

3

8.6

0

0

0.10

Vomiting

3

8.6

1

3.3

0.38